Please use this identifier to cite or link to this item:
|Title:||The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical Trials||Authors:||Giuliani, Jacopo
|Keywords:||Advanced colorectal cancer;Costs of drugs;First-line chemotherapy;Randomized phase II and phase III trials;Targeted biological therapies||Mesh headings:||Colorectal Neoplasms;Drug Therapy;Hepatectomy||Secondary Mesh headings:||Humans||Issue Date:||Dec-2016||Journal:||Journal of gastrointestinal cancer||Abstract:||
The aim of this study was to evaluate the pharmacological costs of conversion chemotherapy with targeted biological agents in an unselected population of advanced colorectal cancer (CRC) patients in order to achieve an R0 liver resection.
|Appears in Collections:||Articles|
Show full item record
checked on Aug 8, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.